Literature DB >> 7870919

Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state.

A L van Steveninck1, R Gieschke, H C Schoemaker, M S Pieters, J M Kroon, D D Breimer, A F Cohen.   

Abstract

Pharmacodynamic interactions of low doses of diazepam and alcohol were investigated in a double blind, randomised, 2 x 2 factorial, cross-over study in eight healthy volunteers. Alcohol or glucose 5% were administered intravenously at rates calculated to maintain breath alcohol levels of 0.5 g/l from 1.5 to 5.5 h after starting the alcohol infusion. Diazepam 5 mg or placebo were administered orally at 1.5 h. Evaluation of pharmacodynamic interactions was performed for the average results of tests performed at 2, 3.5 and 5 h. Plasma concentrations of (desmethyl-) diazepam and breath alcohol levels were measured for pharmacokinetic analysis. Breath alcohol reached pseudo steady state levels of 0.38 g/l (range: 0.24-0.57) after alcohol alone and 0.37 g/l (range: 0.27-0.52) in combination with diazepam. Alcohol effects were demonstrated for latency of saccadic eye movements, smooth pursuit eye movements and subjective drug effects. Diazepam impaired smooth pursuit and saccadic eye movements, adaptive tracking, digit symbol substitution and body sway. The effects of combined alcohol and diazepam were mostly additive without significant synergistic interactions. However, in two subjects large supra-additive effects occurred at 3.5 h following alcohol+diazepam, which were not explained by increased drug levels. The design and methods used in this study proved advantageous in evaluating low dose pharmacodynamic interactions. Despite the absence of significant synergistic interactions, unanticipated impairment of performance may occur in susceptible individuals when taking combined low doses of alcohol and diazepam.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7870919     DOI: 10.1007/bf02244655

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  28 in total

1.  Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual volunteers.

Authors:  A L van Steveninck; S Verver; H C Schoemaker; M S Pieters; R Kroon; D D Breimer; A F Cohen
Journal:  Clin Pharmacol Ther       Date:  1992-10       Impact factor: 6.875

Review 2.  This and that: drug tolerance and great expectations.

Authors:  B Max
Journal:  Trends Pharmacol Sci       Date:  1990-10       Impact factor: 14.819

3.  The pharmacodynamics of ethanol: effects on performance and judgment.

Authors:  F M Gengo; C Gabos; C Straley; C Manning
Journal:  J Clin Pharmacol       Date:  1990-08       Impact factor: 3.126

4.  Reproducibility of individual rates of ethanol metabolism in fasting subjects.

Authors:  G T Passananti; C A Wolff; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1990-03       Impact factor: 6.875

5.  Experimental model for the investigation of kinetic and/or dynamic interactions between drugs and ethanol in humans.

Authors:  D Hartmann; A Flückiger; W H Ziegler; U Timm; M Zell
Journal:  J Pharm Sci       Date:  1988-04       Impact factor: 3.534

Review 6.  Drinking and driving: choosing the legal limits.

Authors:  J A Dunbar; A Penttila; J Pikkarainen
Journal:  Br Med J (Clin Res Ed)       Date:  1987-12-05

7.  Is there acute tolerance to alcohol at steady state?

Authors:  H L Kaplan; E M Sellers; C Hamilton; C A Naranjo; P Dorian
Journal:  J Stud Alcohol       Date:  1985-05

8.  Specific oculomotor deficit after diazepam. I. Saccadic eye movements.

Authors:  S J Rothenberg; D Selkoe
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

9.  Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam.

Authors:  A F Cohen; L Ashby; D Crowley; G Land; A W Peck; A A Miller
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

10.  The myth of "the average alcohol response".

Authors:  T E Reed
Journal:  Alcohol       Date:  1985 May-Jun       Impact factor: 2.405

View more
  18 in total

1.  Central nervous system effects of alcohol at a pseudo-steady-state concentration using alcohol clamping in healthy volunteers.

Authors:  Remco W M Zoethout; Rik C Schoemaker; Lineke Zuurman; Hans van Pelt; Albert Dahan; Adam F Cohen; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

2.  Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers.

Authors:  Anne C Baakman; Rob Zuiker; Joop M A van Gerven; Nicholas Gross; Ronghua Yang; Michael Fetell; Ari Gershon; Yossi Gilgun-Sherki; Edward Hellriegel; Ofer Spiegelstein
Journal:  Br J Clin Pharmacol       Date:  2019-03-14       Impact factor: 4.335

3.  Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation.

Authors:  Lenneke Schrier; Rob Zuiker; Frans W H M Merkus; Erica S Klaassen; Zheng Guan; Bert Tuk; Joop M A van Gerven; Ronald van der Geest; Geert Jan Groeneveld
Journal:  Br J Clin Pharmacol       Date:  2016-12-20       Impact factor: 4.335

4.  An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine.

Authors:  Anne Catrien Baakman; Ricardo Alvarez-Jimenez; Robert Rissmann; Erica S Klaassen; Jasper Stevens; Sebastiaan C Goulooze; Jeroen C G den Burger; Eleonora L Swart; Joop M A van Gerven; Geert Jan Groeneveld
Journal:  Br J Clin Pharmacol       Date:  2017-04-08       Impact factor: 4.335

Review 5.  Biomarkers for the effects of benzodiazepines in healthy volunteers.

Authors:  S J de Visser; J P van der Post; P P de Waal; F Cornet; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

6.  The central nervous system effects of the partial GABA-Aα2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males.

Authors:  Xia Chen; Gabriël Jacobs; Marieke de Kam; Judith Jaeger; Jaakko Lappalainen; Paul Maruff; Mark A Smith; Alan J Cross; Adam Cohen; Joop van Gerven
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

7.  Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects.

Authors:  Benjamin Berger; Sander Brooks; Rob Zuiker; Muriel Richard; Clemens Muehlan; Jasper Dingemanse
Journal:  CNS Drugs       Date:  2020-11-18       Impact factor: 5.749

8.  Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.

Authors:  Erik T te Beek; Justin L Hay; Jonathan N Bullman; Clare Burgess; Kimberly J Nahon; Erica S Klaassen; Frank A Gray; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

9.  Prevalence and correlates of co-ingestion of prescription tranquilizers and other psychoactive substances by U.S. high school seniors: Results from a national survey.

Authors:  Ty S Schepis; Brady T West; Christian J Teter; Sean Esteban McCabe
Journal:  Addict Behav       Date:  2015-08-12       Impact factor: 3.913

10.  A comparative study of two methods for attaining constant alcohol levels.

Authors:  Remco W M Zoethout; Joop M A van Gerven; Glenn J H Dumont; Sunita Paltansing; Nathalie D van Burgel; Monique van der Linden; Albert Dahan; Adam F Cohen; Rik C Schoemaker
Journal:  Br J Clin Pharmacol       Date:  2008-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.